ATXS
Price
$3.92
Change
-$0.00 (-0.00%)
Updated
May 23 closing price
Capitalization
221.22M
78 days until earnings call
XENE
Price
$29.75
Change
-$0.74 (-2.43%)
Updated
May 23 closing price
Capitalization
2.28B
74 days until earnings call
Interact to see
Advertisement

ATXS vs XENE

Header iconATXS vs XENE Comparison
Open Charts ATXS vs XENEBanner chart's image
Astria Therapeutics
Price$3.92
Change-$0.00 (-0.00%)
Volume$245.44K
Capitalization221.22M
Xenon Pharmaceuticals
Price$29.75
Change-$0.74 (-2.43%)
Volume$945.54K
Capitalization2.28B
ATXS vs XENE Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. XENE commentary
May 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 25, 2025
Stock price -- (ATXS: $3.92 vs. XENE: $29.75)
Brand notoriety: ATXS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 51% vs. XENE: 92%
Market capitalization -- ATXS: $221.22M vs. XENE: $2.28B
ATXS [@Biotechnology] is valued at $221.22M. XENE’s [@Biotechnology] market capitalization is $2.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ATXS and XENE are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -1.01% price change this week, while XENE (@Biotechnology) price change was -1.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.28B) has a higher market cap than ATXS($221M). XENE YTD gains are higher at: -24.107 vs. ATXS (-56.152). ATXS has higher annual earnings (EBITDA): -111.56M vs. XENE (-276.74M). XENE has more cash in the bank: 627M vs. ATXS (328M). ATXS has less debt than XENE: ATXS (5.35M) vs XENE (9.02M). ATXS (0) and XENE (0) have equivalent revenues.
ATXSXENEATXS / XENE
Capitalization221M2.28B10%
EBITDA-111.56M-276.74M40%
Gain YTD-56.152-24.107233%
P/E RatioN/AN/A-
Revenue00-
Total Cash328M627M52%
Total Debt5.35M9.02M59%
FUNDAMENTALS RATINGS
ATXS vs XENE: Fundamental Ratings
ATXS
XENE
OUTLOOK RATING
1..100
3810
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10048
SMR RATING
1..100
9460
PRICE GROWTH RATING
1..100
9487
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (58) in the Biotechnology industry is in the same range as XENE (75). This means that ATXS’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (48) in the Biotechnology industry is somewhat better than the same rating for ATXS (100). This means that XENE’s stock grew somewhat faster than ATXS’s over the last 12 months.

XENE's SMR Rating (60) in the Biotechnology industry is somewhat better than the same rating for ATXS (94). This means that XENE’s stock grew somewhat faster than ATXS’s over the last 12 months.

XENE's Price Growth Rating (87) in the Biotechnology industry is in the same range as ATXS (94). This means that XENE’s stock grew similarly to ATXS’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for ATXS (100). This means that XENE’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSXENE
RSI
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 3 days ago
64%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
74%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 20 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
80%
Aroon
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SSCPX6.54-0.03
-0.46%
Saratoga Small Capitalization I
WSBFX21.82-0.16
-0.73%
Boston Trust Walden Balanced
MBIRX51.50-0.42
-0.81%
Morgan Stanley Insight IR
FICHX12.92-0.11
-0.84%
Cantor Fitzgerald Large Cap Fcs Cl Inst
TMPRX53.64-0.55
-1.01%
Touchstone Mid Cap R6

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
N/A
XENE - ATXS
55%
Loosely correlated
-2.43%
CRNX - ATXS
54%
Loosely correlated
-1.16%
KYMR - ATXS
54%
Loosely correlated
-2.12%
TRDA - ATXS
53%
Loosely correlated
-1.57%
APGE - ATXS
52%
Loosely correlated
-2.18%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with ATXS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-2.43%
ATXS - XENE
55%
Loosely correlated
N/A
CRNX - XENE
53%
Loosely correlated
-1.16%
IDYA - XENE
53%
Loosely correlated
-1.72%
KYMR - XENE
52%
Loosely correlated
-2.12%
RCKT - XENE
50%
Loosely correlated
-4.86%
More